FindTrial
Sign In

Database study on the current treatment status of elderly HER2-positive AGC patients

Database study on the current treatment status of elderly HER2-positive AGC patients - Database study on the current treatment status of elderly HER2-positive AGC patients

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000056537
Enrollment
Unknown
Registered
2024-12-23
Start date
2024-12-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive gastric cancer

Interventions

None listed

Sponsors

Daiichi Sankyo Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who meet all the following conditions: Patients with disease codes (ICD-10 codes) for malignant neoplasms of stomach or esophagus Patients with a history of trastuzumab administration Patients who are 18 years of age or older at the start of 1L therapy.

Exclusion criteria

Exclusion criteria: Patients with disease codes for the following conditions are excluded: Patients who underwent gastric resection before and after 1L chemotherapy

Design outcomes

Primary

MeasureTime frame
Treatment regimen proportion for patients with HER2-positive aGC from 1L to 5L. The transition proportion to next line treatment for patients with HER2-positive aGC from 1L to 4L. Time to treatment failure (TTF), Duration of therapy, 1L regimen selection factors, Treatment transition factors, Treatment duration factors.—

Countries

Japan

Contacts

Public ContactKenji Tsuchida

Daiichi Sankyo Co., Ltd. Oncology Medical Science Department I

kenji.tsuchida@daiichisankyo.com03-6225-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026